广州华津医药科技

Huajin Pharma is a clinical-stage biopharmaceutical company based in Guangzhou, China, dedicated to the development of novel enzyme-based therapeutics for oncology and metabolic diseases. The company leverages its expertise in protein engineering and PEGylation technology to develop long-acting recombinant human enzymes with optimized pharmacological properties. Its lead product candidate, HJP-273, is a PEGylated recombinant human arginase 1 currently being evaluated in clinical trials for the treatment of advanced solid tumors, including hepatocellular carcinoma, and the rare metabolic disorder hyperargininemia. Huajin Pharma aims to address significant unmet medical needs by depleting specific amino acids required for tumor growth or replacing deficient enzymes in metabolic pathways. The company has established a robust R&D infrastructure and is expanding its pipeline to include multiple innovative biologics targeting metabolic and malignant conditions.